Vopimetostat's 92% ORR in MTAP-deleted PDAC drives a registrational Phase 3 bet; whether that signal survives randomization against standard of care determines the thesis

Bull

Regulatory authorities validate a streamlined Phase 3 design — likely a randomized two-arm study with OS or PFS as primary endpoint in biomarker-selected MTAP-deleted first-line PDAC — that preserves the combination signal while being achievable in a rare subset. A clean design alignment with FDA/EMA would confirm clinical translatability of the single-arm data and position vopimetostat plus daraxonrasib as potentially the first molecularly targeted regimen to displace gemcitabine/nab-paclitaxel in a defined PDAC subset, dramatically de-risking the registrational path and justifying the capital deployed.

Bear

Regulators require a larger-than-expected sample size, additional safety run-in, or a more demanding endpoint (e.g., OS rather than PFS) that renders the trial operationally or financially prohibitive given the low prevalence of MTAP deletion in PDAC (~30% of cases). Alternatively, the combination's tolerability with daraxonrasib — a KRAS G12D inhibitor where dose-limiting toxicities could compound — may require design modifications that delay initiation or dilute the dosing regimen responsible for the efficacy signal, undermining confidence that the Phase 1/2 response rate will survive in a randomized, adequately powered setting.